Kingfisher Capital LLC lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 6.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 2,693 shares of the company’s stock after selling 200 shares during the period. Kingfisher Capital LLC’s holdings in Novo Nordisk A/S were worth $321,000 as of its most recent filing with the SEC.
Other institutional investors have also recently bought and sold shares of the company. Financial Counselors Inc. increased its holdings in shares of Novo Nordisk A/S by 1.1% during the third quarter. Financial Counselors Inc. now owns 11,009 shares of the company’s stock worth $1,311,000 after purchasing an additional 115 shares during the period. MayTech Global Investments LLC boosted its position in Novo Nordisk A/S by 14.1% in the third quarter. MayTech Global Investments LLC now owns 254,552 shares of the company’s stock valued at $30,309,000 after buying an additional 31,475 shares in the last quarter. FORA Capital LLC acquired a new position in Novo Nordisk A/S in the 3rd quarter worth about $5,309,000. CreativeOne Wealth LLC increased its position in Novo Nordisk A/S by 158.7% in the 3rd quarter. CreativeOne Wealth LLC now owns 20,463 shares of the company’s stock valued at $2,437,000 after acquiring an additional 12,552 shares during the period. Finally, Cravens & Co Advisors LLC grew its position in shares of Novo Nordisk A/S by 1.6% in the 3rd quarter. Cravens & Co Advisors LLC now owns 8,097 shares of the company’s stock valued at $964,000 after buying an additional 128 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.
Novo Nordisk A/S Price Performance
Shares of NVO opened at $106.13 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market cap of $476.26 billion, a P/E ratio of 34.35, a P/E/G ratio of 1.37 and a beta of 0.42. The stock has a 50 day simple moving average of $113.22 and a two-hundred day simple moving average of $128.18. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15.
Analyst Ratings Changes
Read Our Latest Research Report on Novo Nordisk A/S
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories
- Five stocks we like better than Novo Nordisk A/S
- How to Calculate Options Profits
- 3 Penny Stocks Ready to Break Out in 2025
- What is a Dividend King?
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
- What Are Dividend Champions? How to Invest in the Champions
- Zeta Global Holdings Insiders Buy Stock After Short-Report
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.